Lorazepam News and Research

RSS

Lorazepam linked to shorter progression-free survival in pancreatic cancer patients

Patients with pancreatic cancer who took the benzodiazepine lorazepam (Ativan), commonly prescribed to treat anxiety during cancer treatment, had a shorter progression-free survival than patients who did not, according to results published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).

17 Aug 2023

What is the incidence of COVID-19-associated febrile seizures in children?

Researchers investigated the incidence of febrile seizures among SARS-CoV-2-positive children.

2 Feb 2023

CHLA launches first clinical trial for Down syndrome regression disorder with $5.3 million NIH grant

Children's Hospital Los Angeles has launched the first clinical trial for Down syndrome regression disorder (DSRD), a rare and debilitating condition that affects adolescents and young adults with Down syndrome.

23 Jan 2023

Study: Nearly one-quarter of young sarcoma patients continue to use opioids after treatment completion

New analysis finds more than half of U.S. adolescents and young adults with sarcoma-;a type of cancer in the bones or soft tissues-;are often prescribed opioids to treat their pain.

23 May 2022

Study shows massive variations in prescribing of “comfort kit” medications by hospice agencies

When a person nearing the end of their life enters hospice care, their hospice agency's doctors may prescribe a "comfort kit" of small amounts of medications that their caregivers can give them in case of urgent, distressing symptoms such as severe anxiety, agitation, delirium, nausea and more.

13 May 2022

Identification of long COVID patients using big data

A new preprint exploits big data to come up with some answers as to the incidence, treatment, and impact on healthcare systems of long covid.

26 Oct 2021

Intramuscular droperidol more effective than other drugs for treatment of acute agitation in the ED

In a randomized, double-blind trial of patients with acute undifferentiated agitation in the emergency department, droperidol was more effective for sedation and was associated with fewer episodes of respiratory depression than lorazepam or either dose of ziprasidone.

28 Apr 2021

An overview of withdrawal syndromes following discontinuation of psychotropic drugs

The current issue of Psychotherapy and Psychosomatics reports an article that analyzes the data that are available on what may happen when psychotropic drugs are discontinued.

24 Sep 2020

FDA announces requirement of class-wide labeling changes for benzodiazepines

The U.S. Food and Drug Administration announced today in a Drug Safety Communication that it is requiring an update to the Boxed Warning, the agency's most prominent safety warning, and requiring class-wide labeling changes for benzodiazepines to include the risks of abuse, misuse, addiction, physical dependence and withdrawal reactions to help improve their safe use.

23 Sep 2020

Problem drinkers have higher likelihood of using benzodiazepines

Problem drinkers are more likely than teetotalers and moderate drinkers to take benzodiazepines, a class of sedatives that are among the most commonly prescribed drugs -- and the most abused.

14 Dec 2019

Trial comparing three drugs for status epilepticus

Status epilepticus is a condition that is characterized by repeated seizures and is a medical emergency. Treatment is usually with a Benzodiazepine such as Diazepam or Lorazepam etc. There have been not any studies that look at the comparative benefit of drugs that could be prescribed for those who do not respond to the benzodiazepines. The study titled, “Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus,” was published in the latest issue of the journal New England Journal of Medicine.

1 Dec 2019

MU researchers describe Down syndrome-associated catatonia

Down syndrome, due to an extra chromosome 21, occurs in 250,000 children and adults in the United States, making it the country's most common chromosomal disorder. Inherited heart defects, thyroid cancer, celiac disease and developmental disabilities are common Down syndrome complications.

19 Nov 2019

Study finds misuse of benzodiazepines to be highest among young adults

More than one in eight U.S. adults used benzodiazepines in the past year, up from previous reports. Misuse of the prescription drugs accounted for more than 17 percent of overall use, according to a study published online today in Psychiatric Services in Advance.

17 Dec 2018

Medical cannabis provides relief across dozens of health symptoms, study shows

Utilizing new mobile application technology, researchers at The University of New Mexico found that medical cannabis provides immediate symptom relief across dozens of health symptoms with relatively minimal negative side effects.

11 Sep 2018

Researchers explore ways to help older adults taper off and stop using sedatives

Older adults, especially those who are admitted to hospitals, are at risk for potentially dangerous side effects if they are taking multiple medicines. Taking several medications at the same time is called polypharmacy.

23 Mar 2018

AES releases new guideline to help physicians treat status epilepticus patients effectively

Status epilepticus - continuous or rapid sequential seizure activity for 30 minutes or more - is a medical emergency with a high mortality rate in both children and adults. Prompt and effective treatment is key; therefore the American Epilepsy Society has released a new guideline to help physicians, hospitals, and health systems treat patients effectively.

10 Feb 2016

Citalopram of limited use for dementia-associated agitation

The use of citalopram for the treatment of agitation in Alzheimer’s disease may be limited to a small group of people with moderate agitation and low levels of cognitive impairment, study findings suggest.

19 Jan 2016

Alexza reports interim results from AZ-002 Phase 2a study in epilepsy patients

Alexza Pharmaceuticals, Inc. today announced interim results of its Phase 2a study of AZ-002 (Staccato alprazolam) in epilepsy patients. AZ-002 produced a dose-related decrease in mean Standardized Photosensivity Range (SPR), the primary endpoint in the study.

21 Dec 2015

Turing Pharmaceuticals emphasizes continued availability of Daraprim

Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases and conditions, today emphasizes the continued availability of Daraprim and cautions healthcare providers of proposed alternatives to Daraprim.

20 Dec 2015

Turing Pharmaceuticals acquires rights to market Daraprim (pyrimethamine) in the U.S.

Turing Pharmaceuticals AG today announced that it has acquired the exclusive rights to market Daraprim (pyrimethamine) in the U.S. from Impax Laboratories, Inc. The acquisition by Turing is part of a strategic effort focused on treatments for toxoplasmosis and other serious infectious diseases. The company also announced plans to invest in the development of new drug candidates for toxoplasmosis.

10 Aug 2015